Evidence map›Paper›PMID 41017869›Full record

ArticleDrugs in context2025

Nurses' perceptions on the usability of the Hyrimoz

Charlotte Both, Elena Bachinskaya, Laura Rose, Carol M Antequera, Jessica R Allegretti

Abstract read
In one paragraph

Article in Drugs in context, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Charlotte BothSandoz Group AG, Holzkirchen, Germany.
Elena BachinskayaSandoz Group AG, Holzkirchen, Germany.
Laura RoseSandoz Inc., Princeton, NJ, USA.
Carol M AntequeraDivision of Gastroenterology, Department of Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Jessica R AllegrettiDivision of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hyrimoz Methods: Eligible participants included nurses in the USA currently working within a gastroenterology practice with experience managing inflammatory bowel disease and with reference to adalimumab, Humira Results: A total of 123 nurses completed the survey. Participants rated simplicity of use, ease of performing self-injection, ease of learning to use the pen, ability to use an autoinjector pen independently and ease of preparation as the most important autoinjector attributes. When evaluating devices individually, participants awarded higher ratings to the Hyrimoz Sensoready pen over the Humira pen for all evaluated attributes. The greatest differences were reported for visual feedback mechanisms, ease of performing self-injection and the process to initiate injection. When directly comparing the devices, participants preferred the Hyrimoz Sensoready pen over the Humira pen overall, and for all individual attributes. Visual feedback and buttonless activation were the main qualitative features driving this overall preference. Conclusion: Gastroenterology nurses in the USA expressed strong preferences for the Hyrimoz Sensoready pen

Indexed as

adalimumabadherenceautoinjectorbiosimilarCrohn’s diseaseinflammatory bowel diseaseswitchingulcerative colitis

Identifiers

PMID41017869
PMCPMC12463172

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.